Skip to main content

MoneyWorks4Me

Shilpa Medicare informs about company updates

25 Apr 2022 Evaluate

Shilpa Medicare has informed that the Company, via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has received a NoC from RCGM, Dept of Biotechnology to approach the DCGI to conduct Clinical studies for its Biosimilar Aflibercept - a first from an Indian company. The product is a biosimilar version of EYLEA of Regeneron for which currently there is no other biosimilar version on the Indian market.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1860.00
Dr. Reddys Labs. 1371.20
Cipla 1409.00
Lupin 1990.00
Zydus Lifesciences 1195.00
View more..